Kane Biotech Inc. announced that it has made its first commercial-scale sale of revyve? Antimicrobial Wound Gel product (?revyve??) to ProgenaCare Global LLC (?ProgenaCare?). Kane has now completely fulfilled its obligation related to the USD 500,000 initial manufacturing scale up fee received upon signing an exclusive distribution agreement for the US wound care market in May 2023, after receiving U.S. Food and Drug Administration 510(k) clearance for revyve? Antimicrobial Wound Gel. Kane has subsequently been working with Halo Pharma on the technology transfer and manufacturing scale-up phases of product commercialization.
Kane recently presented new in vitro data on the efficacy of revyve? Antimicrobial Wound Gel at the Symposium on Advanced Wound Care (SAWC), Special Operations Medical Association (SOMA), and Medical Technology Enterprise Consortium (MTEC) conferences.